{
    "clinical_study": {
        "@rank": "78762", 
        "acronym": "BUP/NXT-VIVI", 
        "arm_group": {
            "arm_group_label": "BUP/VLNXT to VIVITROL", 
            "arm_group_type": "Experimental", 
            "description": "On days 1-4, participants will receive buprenorphine/naloxone daily at a starting dose of between 4 to 8 mg, progressively decreasing to 2 mg on by day 4. Participants will also receive very low dose naltrexone (VLNTX) at a dose of 0.25 mg on Days 1-3, 2.5 mg on Day 4 and between 10 and 50 mg on Days 5-7. Then a VIVITROL (extended release naltrexone) injection, 380 mg, will be administered on Day 8."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate a very low dose naltrexone-buprenorphine treatment\n      to transfer opioid dependent individuals to extended release naltrexone injection\n      (Vivitrol). The hypothesis is that patients will complete the transfer to Vivitrol\n      successfully, finding the treatment acceptable and showing minimal withdrawal discomfort."
        }, 
        "brief_title": "Low Dose Naltrexone-buprenorphine Transfer to Vivitrol Injection in Opioid Dependence", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Opiate Dependence", 
        "condition_browse": {
            "mesh_term": "Opioid-Related Disorders"
        }, 
        "detailed_description": {
            "textblock": "Twenty opioid dependent (OD) volunteers seeking treatment will be enrolled in an open-label,\n      flexible-dosing, outpatient trial at Duke Addictions Program. On days 1-4, participants will\n      receive buprenorphine/naloxone daily at a starting dose of between 4 to 8 mg, progressively\n      decreasing to 2 mg on by day 4. Participants will also receive very low dose naltrexone\n      (VLNTX) at a dose of 0.25 mg on Days 1-3, 2.5 mg on Day 4 and between 10 and 50 mg on Days\n      5-7. Then a VIVITROL injection, 380 mg, will be administered on Day 8.\n\n      Evaluations will occur daily for up to 6 hours until 1 day after VIVITROL injection and then\n      weekly for 4 weeks.  Patients will receive ancillary medications as needed and weekly\n      psychosocial intervention. At the end of the study, participants will be offered outpatient\n      treatment of OD at the study site, or will be referred to other treatment programs."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Men and women 18 to 65 years of age who meet DSM-IV criteria for OD of at least six\n             months duration, supported by a positive urine for opiates and a positive naloxone\n             challenge test if the diagnosis is unclear.\n\n          2. Individuals must be capable of giving informed consent and capable of complying with\n             study procedures.\n\n          3. Participants will be asked to provide locator information including the address and\n             telephone number of a non-drug abusing relative or friend who can reach the\n             participant in emergencies.\n\n        Exclusion Criteria:\n\n          1. Individuals currently prescribed or regularly taking opiates for chronic pain or\n             medical illness.\n\n          2. Individuals regularly using licit or illicit methadone or BUP.\n\n          3. Individuals meeting DSM-IV criteria for schizophrenia, schizoaffective or psychotic\n             disorders, or psychiatric disorder (other than substance abuse) requiring\n             intervention.\n\n          4. Individuals who are medically unstable, or have liver enzyme function tests greater\n             than two times normal.\n\n          5. Individuals with current suicidal risk or 1 or more suicide attempts within the past\n             year.\n\n          6. History of accidental drug overdose in the last three years or any other significant\n             history of overdose following detoxification, defined as an episode of opioid-induced\n             unconsciousness or incapacitation.\n\n          7. Nursing/pregnant women, or failure in a sexually active man or woman to use adequate\n             contraceptive methods (e.g., oral or depot contraceptives, foam, sponges, and/or\n             condoms)\n\n          8. Individuals who are dependent on any other drugs (excluding nicotine)\n\n          9. Individuals with known sensitivity to BUP, VIVITROL, NTX, naloxone.\n\n         10. Individuals who are court-mandated to treatment.\n\n         11. Individuals who have a current or pending legal status, or any other condition that\n             would make them unlikely to be available for the duration of the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01690546", 
            "org_study_id": "Pro00036909"
        }, 
        "intervention": [
            {
                "arm_group_label": "BUP/VLNXT to VIVITROL", 
                "description": "On days 1-4, participants will receive buprenorphine/naloxone daily, starting at a dose of 4 to 8 mg, progressively decreasing to 2 mg on Days 1-4 and very low dose naltrexone at 0.25 mg on Days 1-3, 2.5 mg on Day 4 and 10 mg to 50 mg on Days 5-7. VIVITROL injection will be administered on Day 8 at 380 mg.", 
                "intervention_name": "very low dose naltrexone", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BUP/VLNXT to VIVITROL", 
                "description": "On days 1-4, participants will receive buprenorphine/naloxone daily, starting at a dose of 4 to 8 mg, progressively decreasing to 2 mg on Days 1-4 and very low dose naltrexone at 0.25 mg on Days 1-3, 2.5 mg on Day 4 and 10 mg to 50 mg on Days 5-7. VIVITROL injection will be administered on Day 8 at 380 mg.", 
                "intervention_name": "extended release naltrexone", 
                "intervention_type": "Drug", 
                "other_name": "Vivitrol"
            }, 
            {
                "arm_group_label": "BUP/VLNXT to VIVITROL", 
                "description": "On days 1-4, participants will receive buprenorphine/naloxone daily, starting at a dose of 4 to 8 mg, progressively decreasing to 2 mg on Days 1-4 and very low dose naltrexone at 0.25 mg on Days 1-3, 2.5 mg on Day 4 and 10 mg to 50 mg on Days 5-7. VIVITROL injection will be administered on Day 8 at 380 mg.", 
                "intervention_name": "buprenorphine/naloxone", 
                "intervention_type": "Drug", 
                "other_name": "Suboxone"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Buprenorphine", 
                "Analgesics, Opioid", 
                "Naltrexone", 
                "Naloxone"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Opioid Addiction", 
            "Addiction", 
            "Drug Dependence"
        ], 
        "lastchanged_date": "February 11, 2014", 
        "location": {
            "contact": {
                "email": "josephine.white@duke.edu", 
                "last_name": "Josephine E White-Harper, BA", 
                "phone": "919-681-0613"
            }, 
            "facility": {
                "address": {
                    "city": "Durham", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "27713"
                }, 
                "name": "Duke University Medical Center / Civitan Building"
            }, 
            "investigator": {
                "last_name": "Paolo Mannelli, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open Label, Flexible Dose Study of Very Low Doses of Naltrexone-Buprenorphine Transfer to Extend-Release Naltrexone (VIVITROL\u00ae) in Opioid Addiction", 
        "overall_contact": {
            "email": "josephine.white@duke.edu", 
            "last_name": "Josephine E White-Harper, BA", 
            "phone": "919-681-0613"
        }, 
        "overall_official": {
            "affiliation": "Duke University Health Systems", 
            "last_name": "Paolo Mannelli, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "After the initial titration period for opioid withdrawal (of up to 8 days), patients will receive the Vivitrol injection. Then, we will follow patients for retention out to 4 weeks and record the total time they remained in treatment.", 
            "measure": "Retention in Treatment", 
            "safety_issue": "No", 
            "time_frame": "4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01690546"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Duke University Medical Center", 
            "investigator_full_name": "Paolo Mannelli", 
            "investigator_title": "Associate Professor of Psychiatry", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "After the initial titration period for opioid withdrawal (of up to 8 days), patients will receive the Vivitrol injection. Then, we will follow patients for retention out to 4 weeks and record the total time they remained in treatment.\nCOWS = Clinical Opiate Withdrawal Scale. COWS rates eleven common opiate withdrawal signs or symptoms. The summed scores are used in the assessment 5-12 = mild; 13-24 = moderate; 25-36 = moderately severe; more than 36 = severe withdrawal", 
                "measure": "Withdrawal Intensity (COWS)", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "After the initial titration period for opioid withdrawal (of up to 8 days), patients will receive the Vivitrol injection. Then, we will follow patients for retention out to 4 weeks and record the total time they remained in treatment.\nSOWS = Subjective Opiate Withdrawal Scale. SOWS contains 16 symptoms whose intensity the patient rates on a scale of 0 (not at all) to 4 (extremely).", 
                "measure": "Withdrawal Intensity (SOWS)", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }
        ], 
        "source": "Duke University", 
        "sponsors": {
            "collaborator": {
                "agency": "Alkermes", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Paolo Mannelli", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}